February 02, 2024

To
Listing Department,
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza,
Bandra Kurla Complex, Bandra (E).
MUMBAI -400 051

Company Code No. AUROPHARMA

To
The Corporate Relations Department
BSE LIMITED
Phiroze Jeejeebhoy Towers,
25th floor, Dalal Street,
MUMBAI -400 001

Company Code No. 524804

Dear Sir/Madam,

Sub: Completion of US FDA Inspection at Unit III of Eugia Pharma Specialities Ltd. (a wholly owned subsidiary) – Reg.,

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

The United States Food and Drug Administration (US FDA) inspected Unit-III, a Formulation manufacturing facility, of Eugia Pharma Specialities Ltd., a wholly owned subsidiary of the Company, situated at Pashamylaram, Patancheru Mandal, Sangareddy District, Telangana, from 22nd January to 2nd February 2024.

The inspection closed with 9 observations. We will be responding to these observations within the stipulated time. The company has decided to temporarily stop manufacturing on certain lines to conduct holistic investigation and corresponding partial distribution thereto. The company has already started working with the regulatory authority / third party consultants to accelerate the process and re-start production on those lines at the earliest. At this point in time, we don’t foresee any material impact on the business.

The company remains committed to work closely with the US FDA and continues to enhance its compliance on an ongoing basis.

We will keep the stock exchanges informed if there is any further information relating to the above in the future.

Please take the above information on record.

Thanking you,

Yours faithfully,

For AUROBINDO PHARMA LIMITED

Digitally signed by BADDIGAM ADI REDDY
Date: 2024.02.02 16:12:41 +05’30’
B. Adi Reddy
Company Secretary